AdvertisementAdvertise with NZME.
Stock Takes
Stock Takes: 'Unlikely to impact' - analyst downplays Fonterra-Bega legal dispute
Analyst says risks in Fonterra-Bega legal tangle have been overstated.
Stock Takes: Will reporting season see the end of a bear market?
Fisher and Paykel Healthcare will be the main event when it reports on May 28.
What’s next for NZ stocks after a poor first quarter? Stock Takes
New Zealand shares suffered a poor first quarter, driven by sickly corporate earnings.
Stock Takes: Has ethical investing lost its shine?
The change of Government in the United States has put ESG investing on the back foot.
Stock Takes: Is gold a good bet?
Gold has hit a record high this week but is it a good investment?
Stock Takes: Focus turns to second half after RBNZ rate cut
Focus has turned to those companies who will benefit from this week's RBNZ rate cut.
Stock Takes: Better times ahead for NZX-listed dairy companies?
Synlait is back in action after a terrible 2024, while trade tension overhangs FPH.
Stock Takes: Air NZ banks on loyal fliers for revenue boost
Analysts upgrade airline's rating but are dubious about some of its revenue plans.
Stock Takes: The big issues facing F&P Healthcare
F&P Healthcare's share price has held despite concerns about the US health sector.
Stock Takes: F&P Healthcare rebounds, tech sector surges and what next for cannabis company?
F&P Healthcare recovers after a sell-off, and what's in store now for Cannasouth.
Stock Takes: Life in the fast lane - the auto stocks bucking NZ’s downtrend
And will new car dealership Armstrong’s try listing on the sharemarket again?
Stock Takes: Why a $4 billion deal fell over
The failed Ebos deal would have been a big bite for investors.
Stock Takes: NZ Shareholders Association on seeing the wood for the trees
The NZSA has questioned the timeliness of PGW's disclosure.
Is this tech company the next Xero?
This freshly listed tech start-up is back by Sir Owen Glenn.
'NZ is in a tough patch': Why our economy is looking like the US during the GFC
Fisher Funds' Ashley Gardyne weighs in on how markets have performed.
Why is there such a dearth of companies listing on the NZX?
It has been months since the last listing on the NZ Stock Exchange.
How this NZ pharma firm prices drugs to avoid villain status
This NZ drug maker says it puts health above wealth.
No easy fix for high inflation environment
Fisher Funds portfolio manager Matt Peek talks about the impact of the Budget.
A capital raise for Synlait - or something more radical for balance sheet woes?
Stock Takes: Is the underperforming Synlait Milk heading toward another capital raise?